Ectonucleotidase CD39 expression in regional metastases in head and neck cancer. (3rd April 2018)

• Record Type: Journal Article
• Authors: Mandapathil, Magis; Boduc, Mehtap; Roessler, Marion; Güldner, Christian; Walliczek-Dworschak, Ute; Mandic, Robert
• Is Part Of: Acta oto-laryngologica. Volume 138:Number 4(2018)
• Page Start: 428
• Page End: 432
• Publication Date: 2018-04-03
• Subjects: Head and neck cancer -- lymph node metastases -- ectonucleotidases -- CD39; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.1080/00016489.2017.1405278
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Introduction: CD39 is the rate-limiting enzyme in the generation of immunosuppressive adenosine and its expression and activity are significant in tumor progression. Squamous cell carcinoma of the head and neck (HNSCC) shows an overall poor prognosis due to high local recurrence rates and early metastatic spread. Material and methods: Primary tumor specimens and lymph node specimens harvested during neck dissection of 65 patients with a diagnosis of HNSCC were subjected to immunohistochemical and H-score analysis of CD39 expression. Demographics, histopathology and subsequent outcome were analyzed. Results: The primary cancer was squamous cell carcinoma in all patients (male/female 55:10). H-score for CD39 expression in the primary lesion and metastatic lymph nodes was significantly higher in advanced compared to early stages with no significant differences among different tumor locations. High intratumoral and intrametastatic CD39 expression was associated with an inferior patients' overall survival at a mean follow-up of 83.4 months (6–204 months). Conclusion: CD39 expression in HNSCC correlated positively with tumor stage and appears to predict poor prognosis. Therefore, CD39 expression in primary lesions and metastatic lymph nodes seems to identify patients at high risk in HNSCC of all tumor sites. Immunotherapeutic approaches targeting CD39 might be promising for this patient population.